In December 7th 2016 an order was issued by the Judicial Panel for Multidistrict Litigation states that those lawsuits which claims that diabetes medications Invokana and Invokamet cause ketoacidosis, kidney damage, and other injuries were transferred to New Jersey District Court for consolidation. As per the order all the lawsuits from districts in Georgia, Illinois, Kentucky, Missouri, Louisiana, Minnesota, Virginia and West Virginia are consolidated to the New Jersey District Court before U.S. District Judge Brian R. Martinotti. After inspecting pretrial proceedings of several Invokana and Invokamet lawsuits centralized in the District of New Jersey the U.S. District Court Judge granted permission to the plaintiffs to file their lawsuits directly in Federal Multidistrict Litigation. The order was issued on March 10th to promote judicial efficiency and eliminate delays of the lawsuits transfer and removal from other federal district courts. As per a report by JPML on Dec. 15 there were 63 Invokana cases filed as part of the multidistrict litigation and according to an updated report released on January 17th by JPML the number of lawsuits rises to 100 and more cases are expected to be filed in the future.
Invokana (canagliflozin) is one of several “new generation” type 2 diabetes drugs known as SGLT2 inhibitors approved on March 29, 2013 by U.S Food and Drugs Administration. The drug inhibits normal kidney function to allow patients to pass excess blood glucose through urination. It is manufactured by Janssen Pharmaceuticals, a division of Johnson & Johnson. Janssen also markets Invokamet, a combination of canagliflozin and metformin. Johnson & Johnson and its subsidiary, Janssen Pharmaceuticals, are facing thousands of Invokana lawsuits due to serious injury caused by Invokana. Healthcare professionals and patients are encouraged to report adverse events or side effects related to the use of Invokana medication. It will help FDA for further investigations as well as in clinical trials. The FDA has taken measures to warn patients. But Invokana still remains on the market. The agency has to take action to protect consumers from dangerous medicines and ban these life threatening drugs from the market.
In a series of new Invokana lawsuits according to plaintiffs the drug’s manufacturer did nothing. Rather than warn the public, Janssen Pharmaceuticals, a subsidiary of corporate giant Johnson & Johnson, actively defended its product and failed to provide adequate warnings and communications to the medical community and end line consumers of the increased risk of serious and life. Thousands of lawsuits have been filed against Johnson & Johnson, Janssen Pharmaceutical, and their affiliated companies. In all the lawsuits the allegations are similar. Manufacturers and marketers present this medication in market to provide cure for Type 2 diabetes that if not treated properly increase the risk for various serious problems such as high blood pressure, nerve damage, heart disease, gastro paresis, blindness, foot complications, kidney failure, stroke and etc. In last year May the U.S. Food and Drug Administration has issued a warning about the risk of ketoacidosis that may occur after taking the anti diabetic medication, Invokana. Diabetic ketoacidosis (DKA) is a serious condition that can lead to diabetic coma (passing out for a long time) or even death.
If you or someone you love who was prescribed Invokana and then suffered from ketoacidosis, kidney failure, Heart Attack or Stroke may be eligible to file a personal injury lawsuit against the drug’s manufacturer. The Drugsclaim Lawyers and Attorneys are investigating claims that Invokana may be linked to kidney failure, cardiovascular complications and bone fractures. In filing personal injury lawsuits, injured patients seek compensation for medical expenses, lost work and pain and suffering, among other damages.